$1.44
-0.04 (-2.70%)
Open$1.53
Previous Close$1.48
Day High$1.53
Day Low$1.31
52W High$8.34
52W Low$1.33
Volume—
Avg Volume82.6K
Market Cap6.62M
P/E Ratio—
EPS$-4.46
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,269.4% upside
Current
$1.44
$1.44
Target
$19.72
$19.72
$18.07
$19.72 avg
$32.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 850.6K | 846.2K | 822.4K |
| Net Income | -189,460 | -228,334 | -201,883 |
| Profit Margin | -22.3% | -27.0% | -24.6% |
| EBITDA | -320,116 | -324,230 | -315,475 |
| Free Cash Flow | -189,627 | -182,540 | -129,892 |
| Rev Growth | +3.9% | -4.1% | +22.7% |
| Debt/Equity | 0.68 | 0.61 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |